News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Abbott Laboratories (ABT) Introduces Enhanced Version Of Medisense Precision PCx(TM) System

10/19/2005 5:09:23 PM

BEDFORD, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Abbott Laboratories, MediSense Products announces the worldwide launch of the Precision PCx 2.2.1(TM) system, an enhanced version of its hand-held, point-of-care blood glucose testing system. The new system and test strip have been developed based on feedback from diabetes caregivers in the hospital setting. Precision PCx 2.2.1 offers several advantages in the areas of test strip performance, sample application, error reduction, ease-of-use and data management.

The new Precision PCx 2.2.1 system uses TrueMeasure(TM) Technology -- the latest MediSense biosensor technology for blood glucose monitoring. The Precision PCx Plus(TM) test strip is the only hospital glucose test strip with a fill-trigger electrode that minimizes the potential for errors that may occur when not enough blood is applied to the test strip, helping to reduce test strip waste. The proprietary TrueMeasure Technology is also designed to minimize interferences from other substances, such as acetaminophen, ensuring accurate glucose-specific results.

Precision PCx Plus test strips are easy to use, offering flexible sample application. Blood may be applied to the top or end of the test strip (top fill/end fill). The test strips are individually bar-coded and foil-wrapped to help enhance patient safety by minimizing errors due to use of expired test strips or mismatched calibration codes and test strip lots.

"The launch of Precision PCx 2.2.1(TM) reinforces our commitment to offering innovative, point-of-care solutions that address the growing demand for accurate, easy-to-use products with Web-based data management capabilities," said Ed Fiorentino, president, MediSense Products, Abbott Laboratories. "MediSense will continue to develop products that meet the unique needs of our customers and improve health care for people living with diabetes."

Precision PCx 2.2.1 also offers an ergonomic design, high-speed data communications and the capability to interface with Precision Web(TM), a Web- based data management system, also manufactured and marketed by Abbott Laboratories, MediSense Products. Precision Web, which is also capable of interfacing with other point-of-care systems, interfaces with a hospital's laboratory information system, facilitating timely and accurate patient record keeping and accounting. Precision Web provides simultaneous, multi-user access to point-of-care testing information throughout a hospital or health system network based on customizable scope and permission for each user.

Abbott Laboratories, MediSense Products, located in Bedford, Mass., is a leader in the development of products designed to help patients and caregivers better manage diabetes. The company designs, develops and manufactures several leading-edge glucose monitoring systems and test strips for use in both home and hospital settings.

Among its leading brands are Precision Xtra(TM)/Precision Optium(TM), Precision Sof-Tact/ Soft-Sense(TM) and Precision QID(R). Abbott Laboratories, MediSense Products also produces Precision Link(R), a personal diabetes data management system, and distributes Precision Sure-Dose(TM) Insulin Syringes. For more information about MediSense Products, visit us online at

Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals and medical products, including devices and diagnostics. The company employs more than 70,000 people and markets its products in more than 130 countries. In 2002, the company's sales were $17.7 billion. Abbott's news releases and other information are available on the company's Web site at .

Abbott Laboratories

CONTACT: Media, Don Braakman, +1-847-937-1237, or Financial Community,Christy Wistar, +1-847-938-4475, both of Abbott Laboratories

Read at

comments powered by Disqus